Healthy Skepticism Library item: 10494
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Tanne JH.
FDA places 'black box' warning on antidiabetes drugs
BMJ 2007 Jun 16; 334:(7606):1237
http://www.bmj.com/cgi/content/full/334/7606/1237
Abstract:
The US Food and Drug Administration has asked the makers of two antidiabetes drugs-rosiglitazone (marketed as Avandia), made by GlaxoSmithKline, and pioglitazone (Actos), made by Takeda-to place “black box” warnings, the most serious kind, on their labels.
The new labels warn of an increased risk of congestive heart failure, because rosiglitazone and related drugs can cause fluid retention. Andrew von Eschenbach, the FDA’s commissioner, announced the warning at a hearing of the US House of Representatives’ Committee on Oversight and Government Reform last week to examine the FDA’s role in evaluating the safety of rosiglitazone.
The new labels do not address the question of whether these drugs pose an increased risk of heart attacks and strokes.
The cardiovascular risk was raised last month by an article and accompanying editorial in the New England Journal of Medicine (doi: 10.1056/NEJMoa072761). Steven Nissen and Kathy Wolski of the Cleveland Clinic did a . . .
